Avacta Group PLC
RTQ1
Company Profile
Business description
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.
Contact
Unit 20, Ash Way
Thorp Arch Estate
West Yorkshire
WetherbyLS23 7FA
GBRT: +44 1904217070
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
148
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,082.10 | 68.80 | 0.86% |
| CAC 40 | 8,073.98 | 45.70 | 0.57% |
| DAX 40 | 23,154.57 | 167.75 | 0.73% |
| Dow JONES (US) | 41,841.63 | 353.44 | 0.85% |
| FTSE 100 | 8,680.29 | 47.96 | 0.56% |
| HKSE | 24,145.57 | 185.59 | 0.77% |
| NASDAQ | 17,808.66 | 54.58 | 0.31% |
| Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
| NZX 50 Index | 12,154.23 | 11.91 | -0.10% |
| S&P 500 | 5,675.12 | 36.18 | 0.64% |
| S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
| SSE Composite Index | 3,426.13 | 6.57 | 0.19% |